Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Partnership with NPH

22 Feb 2021 07:00

RNS Number : 8078P
Yourgene Health PLC
22 February 2021
 

Reach / Non-Regulatory Announcement 

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

 

Partnership with NPH

 

To provide COVID-19 testing service for Leeds Bradford Airport

 

Manchester, UK - 22 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partnership with Newcastle Premier Health Limited1 ("NPH"), a leading provider of independent medical services in Newcastle and the North East, will supply COVID-19 PCR testing services to Leeds Bradford Airport from the Company's laboratory in Manchester.

 

Yourgene and NPH are partnering with Leeds Bradford Airport2 ("LBA") to offer an onsite COVID-19 service for departing and arriving passengers, and for the local community. NPH has successfully implemented a similar testing service at Newcastle Airport and will now look to mirror that offering at LBA , using Yourgene's Clarigene® SARS-CoV-2 assay and its high throughput COVID-19 service laboratory in Manchester to test samples taken at the airport.

 

Together NPH and Yourgene will be offering 'Test To Release' for arriving international travellers, 'Fit to Fly' test certificates for departing passengers, and also general PCR coronavirus testing for the general public that live in the surrounding region. This testing service becomes available today at the airport in anticipation of a relaxation of lockdown rules in the near future. NPH is the sole provider of COVID-19 testing to LBA and Yourgene is the sole COVID-19 testing provider to NPH for the LBA contract.

 

Yourgene Genomic Services is a UK Government approved COVID-19 private testing provider for the Test to Release for International Travel scheme and for general coronavirus testing, as announced by the Company on 24 December 2020.

 

Lyn Rees, CEO of Yourgene commented: "We are thrilled to be partnering with NPH and Leeds Bradford Airport to offer our accurate, reliable and trusted COVID-19 testing service. While the timing of any lockdown relaxations and increases in passenger traffic are unclear at present, we are primed for when these restrictions are lifted at Leeds Bradford and other travel hubs around the country.

 

"We are proud to be part of the global effort to fight this pandemic by offering a high-class Genomics Services laboratories to our partners."

 

 

1 Newcastle Premier Health Limited is a leading provider of independent medical services in Newcastle and the North East. The Company's wide range of medical services includes General Practice consultations, travel advice and immunisations, occupational health assessments, medical screening, and work specific medical assessments for pilots, divers, seafarers and offshore workers.

 

2 Leeds Bradford Airport (LBA) is a regional travel hub used by over 4 million travellers pre-pandemic.

 

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgene-health.com

Barry Hextall, Chief Financial Officer

 

Joanne Cross, Director of Marketing

 

 

 

 

 

N+1 Singer (Joint Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas

 

 

 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Tel: +44 (0)20 7710 7600

Nicholas Moore / Matthew Blawat / Ben Maddison

 

 

 

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

 Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / Mob: 07584 391 303

 

 

 

    

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATMMTTMTMTBAB
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.